(People's Daily Health Client Chen Linhui) On November 30, Beijing time, the 15th Alzheimer's Clinical Trial Conference (CTAD) opened in San Francisco, USA. Lecanemab (BAN2401), an anti-Aβ amyloid-targeted therapeutic drug, developed by Eisai and , has reached the main endpoint of the global Phase III trial, and the research team reported the Topline results of Clarity AD. The treatment of
targeted amyloid directly hits the source of the disease and reverses the course of Alzheimer's disease, which brings new dawn to the modification and treatment of the disease. Clarity AD is an 18-month global, placebo, double-blind, parallel, controlled, open-ended phase III clinical trial aimed at evaluating the effectiveness and safety of lenkanezumab in the treatment of early stage Alzheimer's disease. 1,795 early AD patients were included in 235 study centers in Japan, the United States, Europe, China, South Korea, Canada, Australia and Singapore (China data was not analyzed this time, and they are still following up), aged 50-90 years.
results showed that after 18 months of receiving this drug, the clinical decline of the total score of the CDR-SB of the clinical dementia scale (CDR-SB) was 27% slower than that of the placebo group, with a difference of -0.45 (p=0.00005). All key secondary endpoints (amyloid deposition, ADAS-Cog, ADCS-MCI-ADL) also achieved highly statistically significant results (p0.01), representing that the patient's cognitive function and living ability were protected.
Chen Xiaochun, chief physician of the Department of Neurology at Union Hospital Affiliated to Fujian Medical University. Photo provided by the interviewee
Chen Xiaochun, chief physician of the Department of Neurology at Union Hospital Affiliated to Fujian Medical University, said, "In clinical practice, intellectuals such as doctors, lawyers, university professors, Internet masters, and corporate executives pay more attention to changes in cognitive functions to visit the doctor, but most of the more dementia patients who come to the outpatient clinic are in the middle and late stages, the quality of life of patients is very low, and the burden on caregivers is also heavy. Therefore, self-identification, early diagnosis and intervention are crucial. Looking forward to following American food medicine After the approval of the Product Supervision Administration (FDA), lunkanezumab can be introduced to the country as soon as possible through the Chinese government's accelerated review and approval policies. Here we also call on the country to pay more attention to the prevention and treatment of early Alzheimer's disease and help more Chinese patients and families. This is the wish and responsibility of every clinician."
Chief physician Jia Jianping, Gaochuang Center for Neurological Diseases, Xuanwu Hospital, Capital Medical University. Photo provided by the interviewee
"This disease usually costs a huge amount of energy and cost to take care of patients. Despite this, caregivers will still wonder whether it is worth choosing high-value treatment. As an experienced front-line clinical doctor, I feel frustrated to see such a situation. I think that in terms of spending, AD needs to be treated at a cost. Because if there is no early treatment, it will greatly increase the later burden. Judging from the experimental results released this time, lunkanezumab has shown positive treatment effects. We encourage patients and their families to receive treatment as soon as possible to delay the progress of the disease." Jia Jianping, director of the Gaochuang Center for Neurological Diseases at Xuanwu Hospital of Capital Medical University, told the People's Daily Health Client reporter.
This drug has brought new breakthroughs to the Alzheimer's disease treatment field, which has been silent for 20 years. It not only gives the doctor a dose of augmentation.
